ストックスクリーナーアプリを入手
0.4371
7.81%
0.03
前日終値:
$0.4071
開ける：
$0.4039
24時間の取引高:
215.98K
Relative Volume:
0.03
時価総額：
$18.81M
収益：
$16.77M
当期純損益:
$-11.87M
株価収益率:
-0.9217
EPS:
-0.4742
ネットキャッシュフロー:
$-5.90M
1週間 パフォーマンス:
+6.79%
1か月 パフォーマンス:
+3.71%
6か月 パフォーマンス:
-13.47%
1年 パフォーマンス:
-64.89%
1日の値動き範囲:
$0.40
$0.4398
1週間の範囲:
$0.40
$0.45
52週間の値動き範囲:
$0.30
$1.39
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
IPA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
0.4371 | 18.81M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.58 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.72 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.94 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.77 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.13 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-25 | 開始されました | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd (IPA) 最新ニュース
Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely? - simplywall.st
H.C. Wainwright sets $50 target for ImmunoPrecise stock - Investing.com Australia
H.C. Wainwright sets $50 target for ImmunoPrecise stock By Investing.com - Investing.com South Africa
ImmunoPrecise Antibodies’ (IPA) “Buy” Rating Reiterated at HC Wainwright - Defense World
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI- - GuruFocus
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods - 01net
ImmunoPrecise Antibodies Aligns with FDA’s Move to Non-Animal Testing - TipRanks
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSaitm with FDA's Shift to Non-Animal Testing Methods - Lelezard
AI Breakthrough: How IPA's LENSai Platform Leads FDA's Historic Shift from Animal Testing - Stock Titan
ImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody Discovery - TipRanks
HC Wainwright Has Positive Outlook of IPA FY2025 Earnings - Defense World
ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
HC Wainwright Has Bearish Forecast for IPA FY2028 Earnings - Defense World
ImmunoPrecise Antibodies’ (IPA) “Speculative Buy” Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Speculative Buy on Immunoprecise stock By Investing.com - Investing.com Australia
Benchmark maintains Speculative Buy on Immunoprecise stock - Investing.com
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2025 Earnings Call Transcript - Insider Monkey
ImmunoPrecise Antibodies (NASDAQ:IPA) Price Target Lowered to $5.00 at HC Wainwright - Defense World
ImmunoPrecise Antibodies Earnings Call Highlights Growth - TipRanks
Immunoprecise stock target cut to $5 by H.C. Wainwright - Investing.com Australia
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates - MSN
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... By GuruFocus - Investing.com Canada
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlig - GuruFocus
ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024) - Yahoo
ImmunoPrecise Antibodies Reports Q3 FY25 Financial Results - TipRanks
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 - 01net
Immunoprecise Antibodies Ltd reports results for the quarter ended January 31Earnings Summary - TradingView
Immunoprecise Antibodies (IPA) Reports Financial Results And Recent Business Highlights For Third Quarter Fiscal Year 2025 - MarketScreener
IMMUNOPRECISE ANTIBODIES Earnings Results: $IPA Reports Quarterly Earnings - Nasdaq
ImmunoPrecise Secures Game-Changing $10M Deal as AI Division Reports 132% Growth - Stock Titan
A Look Ahead: ImmunoPrecise Antibodies's Earnings Forecast - Benzinga
IMMUNOPRECISE ANTIBODIES Earnings Preview: Recent $IPA Insider Trading, Hedge Fund Activity, and More - Nasdaq
Immunoprecise Antibodies Ltd expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Mason Hill Advisors buying at Ascot Resources (AOT) - The Globe and Mail
ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on Friday - Defense World
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q4 Loss, Lags Revenue Estimates - MSN
ImmunoPrecise Antibodies’ (IPA) Buy Rating Reiterated at HC Wainwright - Defense World
ImmunoPrecise partners for cancer drug advancement By Investing.com - Investing.com Australia
What's Going On With ImmunoPrecise Stock Thursday?ImmunoPrecise Antibodies (NASDAQ:IPA) - Benzinga
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. - 01Net
Sector Update: Health Care -March 13, 2025 at 08:52 am EDT - Marketscreener.com
ImmunoPrecise Antibodies Signs Partnership Deal to Develop Cancer Treatments -March 13, 2025 at 07:55 am EDT - Marketscreener.com
ImmunoPrecise Antibodies Partners for $10M Cancer Therapeutics Development - TipRanks
Positive Signs As Multiple Insiders Buy ImmunoPrecise Antibodies Stock - Yahoo Finance
ImmunoPrecise partners for cancer drug advancement - Investing.com
Immunoprecise Antibodies Ltd (IPA) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):